文献速递MDS 与骨髓增殖性肿瘤白血病

塞利尼索治疗低甲基化药物难治性骨髓增生异常综合征或少原始细胞型急性髓系白血病的疗效与安全性:单中心单臂2期试验

Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2020-01-01

这项单中心单臂2期试验纳入25例低甲基化药物难治性高危骨髓增生异常综合征或少原始细胞型急性髓系白血病患者,口服塞利尼索60 mg每周两次连用2周休1周。23例可评估患者总缓解率26%,最常见3-4级不良事件为血小板减少(32%)和低钠血症(20%)。

要点

  • 塞利尼索在低甲基化药物难治性MDS或少原始细胞型AML中显示缓解。
  • 23例可评估患者总缓解率26%,另52%达疾病稳定。
  • 最常见3-4级不良事件为血小板减少(32%)和低钠血症(20%)。

核心结论

  • 塞利尼索在低甲基化药物难治性骨髓增生异常综合征或少原始细胞型急性髓系白血病患者中显示缓解,不良事件经支持治疗可控。
  • 需要进一步研究比较塞利尼索与单纯支持治疗,并识别最可能从塞利尼索治疗中获益的患者亚组。

研究设计与样本

  • 在美国纪念斯隆-凯特琳癌症中心开展的单中心、单臂2期试验,注册号NCT02228525。
  • 纳入18岁及以上、高危骨髓增生异常综合征或少原始细胞型急性髓系白血病(原始细胞≥20%但≤30%)、对低甲基化药物难治、ECOG体能状态评分0-2的患者。
  • 方案为3周一个周期口服塞利尼索60 mg每周两次连用2周后休1周,主要终点为总缓解率。
  • 2014年9月23日至2018年3月13日共入组25例,中位随访8.5个月(IQR 3.1-12.2),23例可评估疗效。

主要发现

  • 23例可评估患者中,6例达骨髓完全缓解,总缓解率26%(95% CI 10-48)。
  • 另有12例(52%,95% CI 31-73)达疾病稳定。
  • 25例患者中最常见3-4级不良事件为血小板减少(8例[32%])和低钠血症(5例[20%])。
  • 无药物相关严重不良事件,无治疗相关死亡。

临床怎么用

  • 作者认为塞利尼索在该难治人群中显示缓解,不良事件经支持治疗可控。
  • 作者建议进一步研究比较塞利尼索与单纯支持治疗,并识别最可能获益的患者亚组。

局限性

  • 单中心、单臂设计。
  • 样本量小(共入组25例,23例可评估疗效)。
  • 需要进一步研究比较塞利尼索与单纯支持治疗,并识别最可能从塞利尼索治疗中获益的患者亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The median overall survival of patients with high-risk myelodysplastic syndromes refractory to hypomethylating agents is less than 6 months. Currently, no standard therapy for such patients exists. Preclinical studies have shown that inhibition of the nuclear export protein exportin 1 (XPO1) causes nuclear accumulation of p53 and disruption of NF-κB signalling, both relevant targets for myelodysplastic syndromes. We therefore aimed to assess the safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents. METHODS: We did a single-centre, single-arm, phase 2 trial at the Memorial Sloan Kettering Cancer Center in the USA. We included patients 18 years or older with high-risk myelodysplastic syndromes or oligoblastic acute myeloid leukaemia (defined as blasts ≥20% but ≤30%) refractory to hypomethylating agents and with an Eastern Cooperative Oncology Group performance status score of 0-2. Eligible patients received 3-week long cycles of oral selinexor (60 mg twice per week for 2 weeks, followed by 1 week off). The primary outcome was overall response rate. Complete remission, partial remission, marrow complete remission, or haematological improvement were included in the response categories for assessing the primary endpoint. The activity analysis included all patients who completed at least one full-scheduled post-treatment disease assessment. All patients who were given selinexor were included in the safety analysis. This study is registered with ClinicalTrials.gov, NCT02228525. FINDINGS: Between Sept 23, 2014, and March 13, 2018, 25 patients were enrolled on this study. The median follow-up was 8·5 months (IQR 3·1-12·2). Two patients did not meet the full eligibility criteria after baseline assessment; therefore, 23 patients were evaluable for activity assessment. In the 23 evaluable patients, overall response rate was 26% (95% CI 10-48) in six patients with marrow complete remission, with an additional 12 patients (52%, 95% CI 31-73) achieving stable disease. The most common grade 3 or 4 adverse events were thrombocytopenia (eight [32%] of 25 patients) and hyponatraemia (five [20%]). There were no drug-related serious adverse events and no treatment-related deaths. INTERPRETATION: Selinexor showed responses in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents. Adverse events were manageable with supportive care implementation. Further studies are needed to compare selinexor with supportive care alone, and to identify patient subgroups that might benefit the most from selinexor treatment. FUNDING: Karyopharm Therapeutics.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Taylor J, Mi X, Penson AV, et al. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2020. PMID: 32735836. doi:10.1016/S2352-3026(20)30209-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。